Stock Movers: Intel, Mission Produce, Tango (Podcast)

Intel rose after a report that Google will rely on it for more than 3 million specialized AI chips in 2028, a potential large-scale validation of its foundry/AI-chip efforts. Mission Produce swung to a loss on lower revenue in fiscal Q2 due to weak avocado prices and harvest delays, though volumes improved and pricing has since strengthened. Tango Therapeutics jumped as much as 48% after early data showed its drug combination shrank tumors in 11 of 12 advanced pancreatic cancer patients, and the company plans a final-stage trial.

Analysis

The tape is being pulled in two very different directions: a long-duration capex winner in INTC and a single-asset clinical readout in TNGX, while AVO is a classic margin reset. The important second-order effect is not just that Google is diversifying TPU sourcing, but that a credible hyperscaler validation can re-rate Intel’s foundry/advanced packaging optionality across the rest of the AI supply chain; if the relationship scales, the market may start assigning value to future customer wins rather than current earnings power. That said, this is still a 2028 revenue story, so the move is more about sentiment and multiple expansion than near-term EPS.

TNGX is the more asymmetric setup because the market is likely discounting a path from early efficacy signal to platform credibility, and pancreatic oncology has a long history of false positives. The key is durability: if responses hold on confirmatory scan and the combo advances quickly into a front-line trial, the stock can stay inflated for months; if not, the drawdown can be violent because biotech rallies on small n are usually mean-reverting. RVMD has a quieter but real read-through: any perceived validation of daraxonrasib as a backbone therapy improves partnering and combination optionality across the KRAS space.

AVO is the opposite trade: the fundamental issue is that price/margin leverage in commodities can swing faster than operating volume growth can offset it. Improving supply conditions help, but if avocado pricing normalizes slowly, the equity can remain under pressure for another 1-2 quarters because investors tend to underwrite peak-margin recovery lazily and then cut estimates sharply once visibility improves. The contrarian point is that the market may be over-penalizing a transitory agricultural margin trough relative to the more structural upside in TNGX/INTC, creating a useful pair structure.

Key Decisions for Investors

• Go long INTC vs short SOXX or a basket of AI semi winners for 1-3 months: thesis is re-rating on strategic foundry validation, not immediate earnings; target a 10-15% relative move if follow-on customer rumors build, but exit if the market fades the headline within 2-3 sessions.
• Initiate a small, event-driven long TNGX call spread or common stock with a tight risk limit for the next 2-6 weeks: favorable only if confirmatory scan cadence and trial design updates keep the story alive; treat as a high-volatility momentum trade with potential for a 2x-3x upside, but size for a binary disappointment.
• Consider a long RVMD / short XBI basket pair over 1-3 months: the read-through is that combination efficacy may increase perceived platform value for daraxonrasib without requiring immediate fundamental upside across the whole sector.
• Short AVO on any rebound toward prior support, or pair it against a long quality ag/consumer staples name for 1-2 quarters: the margin recovery story is still dependent on pricing discipline, and commodity normalization can lag volume improvement by several reporting periods.
• If using options on INTC, prefer call spreads over outright calls into 2028-style narrative re-rating: the near-term catalyst is real, but implied volatility may already be pricing in too much of the upside from a multi-year customer relationship.